Educational only. Not medical advice. Invite-only research preview.No PHI. Do not share patient names or identifying information (HIPAA).
MytoIntelligence
All targets

Molecular target

P2Y12 ADP Receptor

Platelet ADP receptor whose activation amplifies platelet aggregation. Targeted by clopidogrel, prasugrel, ticagrelor — the 'antiplatelet' class distinct from aspirin's COX-1 mechanism.

4 drugs act here0 plants reach it via their compounds

Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.

No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.

Pharmaceutical agents

Drugs that act on P2Y12 ADP Receptor

These medications have P2Y12 ADP Receptor among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.

CangrelorClopidogrelPrasugrelTicagrelor
A shared molecular target shows how a botanical and a drug relate mechanistically. It is not evidence that one can replace the other. Educational summary only — discuss any medication decision with your clinician.